Kenneth J Stenglein

Title: Kenneth J Stenglein: Innovator in Immunoassay Technology

Introduction

Kenneth J Stenglein is a notable inventor based in Portland, OR (US). He has made significant contributions to the field of immunoassays, particularly through his innovative work on topiramate immunoassays. His expertise and dedication to research have led to advancements that benefit both the scientific community and healthcare.

Latest Patents

Kenneth J Stenglein holds a patent for a topiramate immunoassay. This invention provides a method for detecting topiramate, a medication used primarily for epilepsy and migraine prevention. The patent details a process where topiramate is derivatized at the sulfamate moiety or the 9-carbon or 10-carbon methyl group. This allows for the addition of a label bound directly or through a linking group, which can be used as a tracer or to induce anti-topiramate antibodies. The patent also includes methods and kits for conducting the immunoassay.

Career Highlights

Stenglein is associated with Oxis International, Inc., where he applies his knowledge and skills to further develop immunoassay technologies. His work has been instrumental in enhancing the accuracy and efficiency of drug testing and monitoring.

Collaborations

Throughout his career, Kenneth has collaborated with esteemed colleagues such as Daniel B Cawley and Bruce E Maryanoff. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kenneth J Stenglein's contributions to immunoassay technology exemplify the impact of dedicated inventors in the field of healthcare. His patent on topiramate immunoassays showcases his innovative spirit and commitment to advancing medical science.